Pulmonary Medicine

Pediatric respiratory diseases; cystic fibrosis.

Biography

Dr. Boat trained as a pediatrician and pulmonary medicine physician at the University of Minnesota, the National Institutes of Health, and at Case Western Reserve University (CWRU). His first faculty appointment at CWRU, 1972-1982 focused on cystic fibrosis lung dysfunction research related to the role of abnormal mucous secretions in airways and to improving care for these patients.

Dr. Boat next assumed the chair of the Department of Pediatrics at the University of North Carolina (1982-1993) followed by appointment as chair of pediatrics (University of Cincinnati) and director of the Cincinnati Children’s Hospital Research Foundation (1993-2007).

Following leadership roles as CEO of UC Physicians and dean of the University of Cincinnati College of Medicine, Dr. Boat returned to Cincinnati Children’s in November of 2014 as professor of pediatrics in the Division of Pulmonary Medicine within the UC College of Medicine and as director of CF WELL, a learning and education center to promote wellness and quality of life for patients with cystic fibrosis and their families.

Dr. Boat is a member of the Board of Children, Youth and Families of the Institute of Medicine and has been the author of five IOM reports addressing physical, emotional and behavioral dimensions of child health. In these roles he has been a champion for safe and nurturing family environments, as important early contributors to lifetime health and wellness, for all children.

MD: University of Iowa, Iowa City, IA, 1966.

Residency: Pediatrics, University of Minnesota, Minneapolis, MN, 1968.

Certification: Pediatrics, 1972.

Boat TF, Wu J, IOM Report. Mental disorders and disabilities among low-income children. Washington (DC):National Academies Press (US);2015.

Boat TF. Improving lifetime health by promotion behavioral health in children. JAMA. 2015;313:1509-10.

Fields M, Boat TF, IOM Report. Safe and Effective Medicines for Children. Washington (DC):National Academies Press (US);2012.

Fields M, Boat TF, IOM Report. Accelerating Rare Diseases Research and Orphan Products Development. Washington (DC):National Academies Press (US);2010.

Boat TF. Insights From Trends in Biomedical Research Funding. JAMA. 2010;303(2):170-71.

Boat TF, Chao SM, O’Neill PH. From Waste to Value in Health Care. JAMA. 2008;299(5):568-571.

O’Connell ME, Boat TF, Warner KE, National Research Council and Institute of Medicine Report. Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities. Washington (DC):National Academies Press (US);2009.

Boat TF. The Future of Pediatric Research. J Pediatr. 2007 Nov;151(5 Suppl):S21-7.

Britto MT, Kotagal UR, Boat TF. Listening to families: first steps toward improved hospital care. Arch Pediatr Adolesc Med. 2005 Feb;159(2):187-8.

Abrams MT, Patchan KM, Boat TF. Research Training in Psychiatry Residency: Strategies for Reform. Washington (DC):National Academies Press (US);2003.

Ronald E. Bokulic, DO

513-636-6771

High Res

Ronald E. Bokulic, DO

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-6771

Fax 513-636-4615

Show All

Clinical Interests

Asthma; interstitial lung disease; exercise

DO: Philadelphia College of Osteopathic Medicine, 1983.

Residency: Pediatrics, Children's Medical Center, Dallas, TX.

Fellowship: Pediatric Pulmonary Medicine, Tulane University Medical School, New Orleans, LA.

Certification: Pediatrics, 1989; Pediatric Pulmonology, 1994.

Burrow TA, Cohen MB, Bokulic R, Deutsch G, Choudhary A, Falcone RA Jr, Grabowski GA. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy. J Pediatr. 2007 Feb;150(2):202-6.

Amin RS, Carroll JL, Jeffries JL, Grone C, Bean JA, Chini B, Bokulic R, Daniels SR. Twenty-four-hour ambulatory blood pressure in children with sleep-disordered breathing. Am J Respir Crit Care Med. 2004 Apr 15;169(8):950-6.

Evans DA, Bokulic RE. Radiological case of the month. Posttraumatic pseudocysts. Arch Pediatr Adolesc Med. 1997 Aug;151(8):47-9.

Hardie W, Bokulic R, Garcia VF, Reising SF, Christie CD. Pneumococcal pleural empyemas in children. Clin Infect Dis. 1996 Jun;22(6):1057-63.

Bokulic RE, Hilman BC. Interstitial lung disease in children. Pediatr Clin North Am. 1994 Jun;41(3):543-67.

Barbara Chini, MD Director, Pulmonary Fellowship Program

513-636-6771 barb.chini@cchmc.org

High Res

Barbara Chini, MD

Director, Pulmonary Fellowship Program

Assistant Cystic Fibrosis Center Director, Division of Pulmonary Medicine

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-6771

Fax 513-636-4615

Email barb.chini@cchmc.org

Show All

BS: University of Notre Dame Notre Dame, IN, 1986.

MD: Vanderbilt University Medical School, Nashville, TN, 1990.

Internship: Pediatrics, University of Rochester Medical Center Pediatrics, Rochester, NY, 1991.

Residency: Pediatrics, University of Rochester Medical Center, Rochester, NY, 1993.

Fellowships: University of Rochester Medical Center, Rochester, NY, 1994; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 1997.

Fricke BL, Donnelly LF, Shott SR, Kalra M, Poe SA, Chini BA, Amin RS. Comparison of lingual tonsil size as depicted on MR imaging between children with obstructive sleep apnea despite previous tonsillectomy and adenoidectomy and normal controls. Pediatr Radiol. 2006 Jun;36(6):518-23.

Shott SR, Amin R, Chini B, Heubi C, Hotze S, Akers R. Obstructive sleep apnea – Should all children with Down syndrome be tested? Arch Otolaryngol Head Neck Surg. 2006 Apr;132(4):432-436.

Mannaa M, Chini B. A case in point. A boy with shortness of breath, cough, and myalgias. J Respiratory Diseases. 2006;27(8):356-8.

Beebe DW, Wells CT, Jeffries J, Chini B, Kalra M, Amin RS. Neuropsychological Effects of Pediatric Obstructive Sleep Apnea. JINS. 2004 Nov;10(7):962-975.

Abbott MB, Donnelly LF, Dardzinski BJ, Poe SA, Chini BA, Amin RS. Obstructive Sleep Apnea: MR Imaging Volume Segmentation Analysis. Radiology. 2004 Sep;232(3):889-895.

Amin RS, Carroll J, Bean J, Jeffries J, Chini B, Bokulic R, Daniels S. Twenty Four Hour Ambulatory Blood Pressure in Children with Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2004 Apr;169(8):950-56.

Donnelly LF, Shott SR, Connor RL, Chini BA, Amin RS. Causes of Persistent Obstructive Sleep Apnea Despite Previous Tonsillectomy and Adenoidectomy in Children with Down Syndrome as Depicted on Static and Dynamic Cine MRI. AJR. 2004 Jul;183(1):175-181.

John P. Clancy, MD Gunnar Esiason/Cincinnati Bell Chair

focuses primarily on airway epithelial biology, examining strategies to treat cystic fibrosis and to normalize protease dysregulation in lung inflammatory disorders. The goals of our research program are 1) to examine strategies to restore activity to mutant, disease-causing CFTR mutations, 2) to develop new biomarkers of CFTR activity, and 3) to investigate novel inflammatory pathways.

513-636-6771 john.clancy@cchmc.org

High Res

John P. Clancy, MD

Gunnar Esiason/Cincinnati Bell Chair

Research Director, Division of Pulmonary Medicine

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-6771

Email john.clancy@cchmc.org

Show All

Clinical Interests

Cystic fibrosis; airway cellular biology; CFTR regulation

Biography

John P. Clancy, MD, has served in several leadership roles at Univeristy of Alabama, Cincinnati Children's and within the international cystic fibrosis (CF) community. Some of his leadership roles include membership on the CFF Clinical Research Committee (2003 to present), the CFF-TDN Steering Committee (2002 to 2007), the CFF-TDN Translational Research Center Committee (2008 to present), DSMB membership for the Rare Lung Disease Consortium within the NIH Rare Disease Research Network (2005 to 2009, Chairman from 2010 to present); organizing committee membership for the North American CF Conference (2003 to present) and the European CF Society (2010), co-chair of the CFFT Biomarkers Consortium (2010 to present), member of the Promotion and Tenure Committee for the UAB Department of Pediatrics (2003 to 2010) and the UAB SOM (2007 to 2010, including committee chair).

Dr. Clancy has been the primary or co-mentor of more than 20 fellows, graduate students and junior faculty. He has been the initial recipient of two endowed chairs, including the Raymond K. Lyrene Chair in Pediatric Pulmonary Medicine at the University of Alabama (2005), and the Tom Boat Chair in Cystic Fibrosis Clinical and Translational Research at Cincinnati Children's (2011).

MD: University of Iowa College of Medicine, Iowa City, IA.

Residency: University of Virginia, Charlottesville, VA.

Fellowship: University of Alabama at Birmingham, Birmingham, AL.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, Deboeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012 Jan;67(1):12-8.

Hug MJ, Derichs N, Bronsveld I, Clancy JP. Measurement of ion transport function in rectal biopsies. Methods Mol Biol. 2011;741:87-107.

Rowe SM, Clancy JP, Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol. 2011;741:69-86.

Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003.

Clancy JP. Diagnosing cystic fibrosis in patients with non-diagnostic results: the case for intestinal current measurements. Thorax. 2010 Jul;65(7):575-6.

Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L, Li Y, Fortenberry J, Sorscher EJ, Clancy JP. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther. 2010 Aug;23(4):268-78.

Com G, Clancy JP. Adenosine receptors, cystic fibrosis, and airway hydration. Handb Exp Pharmacol. 2009;(193):363-81.

Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs. 2009;23(3):165-74.

Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc. 2007 Aug 1;4(4):387-98.

Rowe SM, Varga K, Rab A, Bebok Z, Byram K, Li Y, Sorscher EJ, Clancy JP. Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol. 2007 Sep;37(3):347-56.

Daniel H. Grossoehme Chaplain, Division of Pulmonary Medicine

researches adherence, spirituality and religion, chronic illness coping and HRQoL.
Visit the Grossoehme Lab.

513-636-0848 daniel.grossoehme@cchmc.org

High Res

Daniel H. Grossoehme

Chaplain, Division of Pulmonary Medicine

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-0848

Fax 513-636-0810

Email daniel.grossoehme@cchmc.org

Show All

Adherence; spirituality and religion; chronic illness coping and HRQoL.
Visit the Grossoehme Lab.

Biography

Daniel H. Grossoehme, MDiv, BCC, is an ordained Episcopal priest who completed his clinical pastoral residency at the Cleveland Clinic Foundation Hospital with an emphasis in pediatrics and critical care in 1992-1993. He became the first director of Chaplaincy Services at Children's Hospital Medical Center of Akron, where he served from 1993 to 2003, when he joined Cincinnati Children's Hospital Medical Center's College Hill Campus as staff chaplain.

Doctor of Ministry: (Pastoral Counseling), Louisville Presbyterian Theological Seminary, 2006.

MDiv: Protestant Episcopal Theological Seminary in Virginia, Alexandria, VA, 1992.

BS: Astrophysics, Indiana University, 1985.

Grossoehme DH, Opipari-Arrigan L, VanDyke R, Thurmond S, Seid M. Relationship of adherence determinants and parental spirituality in cystic fibrosis. Pediatr Pulmonol. 2012 Jun;47(6):558-66.

Grossoehme DH, Jacobson CJ, Cotton S, Ragsdale J, VanDyke R, Seid M. Written prayers and religious coping in a paediatric hospital setting. Mental Health, Religion & Culture. 2011 14(5): 423-432.

Grossoehme DH, Ragsdale JR, Snow A, Seid M. We were chosen as a family: Parents’ evolving use of religion when their child has cystic fibrosis. J Relig Health. 2012 Dec;51(4):1347-58.

Cotton S, Grossoehme DH, McGrady M. Religious coping and use of prayer in sickle cell disease. Pediatric Blood Cancer. 2012 Feb;58(2):244-9.

Grossoehme DH, VanDyke R, Jacobson CJ, Cotton S, Ragsdale J, Seid M. Written prayers in a pediatric hospital: linguistic analysis. Psychology of Religion & Spirituality. 2010 2(4): 227-233.

Grossoehme DH, Ragsdale JR, Wooldridge JL, Cotton S, Grimes L, Seid M. Parents’ use of religious coping in the first year after their child’s chronic illness diagnosis. Journal of Health Care Chaplaincy. 2010 16(3): 109-122.

Grossoehme DH, Ragsdale J, Wooldridge JL, Cotton S, Seid M. We can handle this: Parents’ use of religion in the first year following their child’s diagnosis with cystic fibrosis. Journal of Health Care Chaplaincy. 2010 16(3): 95-108.

Grossoehme DH, VanDyke R, Seid M. Spirituality’s role in chronic disease self-management: Sanctification of the body in families dealing with cystic fibrosis. Journal of Health Care Chaplaincy. 2009 15, 1-10.

Cotton S, Grossoehme D, Rosenthal SL, McGrady ME, Roberts YH, Hines J, Yi MS, Tsevat J. Religious/spiritual coping in adolescents with sickle cell disease: A pilot study. Journal of Pediatric Hematology/Oncology. 2009 31(5), 313-318.

Grossoehme DH, Ragsdale J, Dixon C, Berz K, Zimmer M. The changing face of medical education: the role of religion, integrative medicine and osteopathy. The Open Medical Education Journal. 2009 2, 1-8.

Theresa W. Guilbert, MD, MS Associate Director, Asthma Center

is a pediatric pulmonologist who has research interests in the area of early life risk factors, exposures, and environment interactions that lead to the development of early childhood asthma and recurrent wheezing. Much of Dr. Guilbert’s research experience has been with National Institutes of Health sponsored multi-center trials and networks. Another area of research interest is using clinical electronic medical data.

513-636-6771 theresa.guilbert@cchmc.org

High Res

Theresa W. Guilbert, MD, MS

Associate Director, Asthma Center

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-6771

Email theresa.guilbert@cchmc.org

Show All

Clinical

Preschool wheezing; difficult-to-control asthma

Research

Early life risk factors, exposures, and environment interactions; early childhood asthma; recurrent wheezing; clinical electronic medical data

Biography

Theresa Guilbert, MD, MS, is board certified in pediatrics and pediatric pulmonary and is a professor in the Division of Pulmonary Medicine at Cincinnati Children's within the UC Department of Pediatrics. She is the associate director of the Asthma Center and has 14 years of experience in providing clinical care to children and adolescents with asthma and conducting clinical and epidemiologic research. She has been selected as one of the Best Doctors in America for several years. Dr. Guilbert has been elected to serve on the Pulmonology Subboard of the American Board of Pediatrics, the American Thoracic Society (ATS) Pediatric Planning and the Pediatric Program Committees. In addition, she has trained and mentored several academic pediatric pulmonologists.

MD: University of Minnesota, Minneapolis, MN, 1992.

Residency: Pediatrics, University of Minnesota, Minneapolis, MN.

Fellowship: Pediatric Pulmonology, University of Colorado, Denver, CO.

MS: Epidemiology, University of Arizona, Tucson, AZ, 2007.

Tomasallo C, Hanrahan L, Tandias A, Cowan K, Guilbert TW. Estimating Wisconsin Asthma Prevalence Using Clinical Electronic Health Records and Public Health Data . Am J Public Health . 2014 Jan;104(1):e65-73.

Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, Le Souef P, Mäkelä M, Roberts G, Wong G, Zar H, Akdis CA, Bacharier LB, Baraldi E, van Bever HP, de Blic J, Boner A, Burks W, Casale TB, Castro-Rodriguez JA, Chen YZ, El-Gamal YM, Everard ML, Frischer T, Geller M, Gereda J, Goh DY, Guilbert TW, Hedlin G, Heymann PW, Hong SJ, Hossny EM, Huang JL, Jackson DJ, de Jongste JC, Lalayci O, Aït-Khaled N, Kling S, Kuna P, Lau S, Ledford DK, Lee SI, Liu AH, Lockey RF, Lødrup-Carlsen K, Lötvall J, Morikawa A, Nieto A, Paramesh H, Pawankar R, Pohunek P, Pongracic J, Price D, Robertson C, Rosario N, Rossenwasser LJ, Sly PD, Stein R, Stick S, Szefler, S, Taussig LM, Valovirta E, Vichyanond P, Wallace D, Weinberg E, Wennergren G, Wildhaber J, Zeiger RS. International consensus on (ICON) pediatric asthma . Allergy . 2012 Aug;67(8):976-97.

Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, Strunk RC, Covar R, Szefler SJ, Boehmer S, Jackson DJ, Sorkness CA, Gern JE, Kelly HW, Friedman NJ, Mellon MH, Schatz M, Morgan WJ, Chinchilli VM, Raissy HH, Bade E, Malka-Rais J, Beigelman A, Taussig LM; CARE Network of the National Heart, Lung, and Blood Institute. Daily or intermittent budesonide in preschool children with recurrent wheezing . N Engl J Med . 2011 Nov 24;365(21):1990-2001.

Guilbert TW, Singh AM, Danov Z, Evans MD, Jackson DJ, Burton R, Roberg KA, Anderson EL, Pappas TE, Gangnon R, Gern JE, Lemanske RF Jr. Decreased lung function after preschool wheezing rhinovirus illnesses in children at high risk to develop asthma . J Allergy Clin Immunol . 2011 Sep;128(3):532-8.

Guilbert TW, Mauger DT, Allen DB, Zeiger RS, Lemanske RF, Jr., Szefler SJ, Strunk RC, Bacharier LB; Covar R, Sorkness CA, Taussig LM, Martinez FD, Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Growth of preschool children at high risk for asthma two years after discontinuation of fluticasone. J Allergy Clin Immunol. 2011 Nov;128(5):956-63.

Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM; the Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18;362(11):975-85.

Guilbert TW, Stern DA, Morgan WJ, Martinez FD, Wright, AL. Effect Of Breastfeeding On Lung Function In Childhood And Modulation By Maternal Asthma Atopy. Amer J Respri Crit Care Med. 2007 Nov 1;176(9):843-8.

Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, Lemanske RF Jr, Strunk RC, Allen DB, Bloomberg GR, Heldt G, Krawiec M, Larsen G, Liu AH, Chinchilli VM, Sorkness CA, Taussig LM, Martinez FD. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006 May 11; 354(19):1985-97.

Morgan WJ, Stern DA, Sherrill D, Guerra S, Holberg CJ, Guilbert T, Taussig LM, Wright AL, Martinez FD. Outcome of asthma and wheezing in the first six years of life: follow-up through adolescence. Am J Respir Crit Care Med. 2005 Nov 15;172(10):1253-58.

Guilbert TW, Morgan WJ, Zeiger RS, Bacharier LB, Boehmer SJ, Krawiec M, Larsen G, Lemanske, Jr. RF, Liu A, Mauger DT, Sorkness C, Szefler SJ, Strunk RC, Taussig LM, Martinez FD. Atopic Characteristics of Children with Recurrent Wheezing at High-risk for the Development of Childhood Asthma. J Allergy Clin Immunol. 2004 Dec;114(6):1282-7.

William D. Hardie, MD

Visit the Hardie Lab.

513-636-6771 william.hardie@cchmc.org

High Res

William D. Hardie, MD

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-6771

Fax 513-636-4615

Email william.hardie@cchmc.org

Show All

Clinical

Pulmonary function tests; pneumonia; empyema

Research

Growth factors in lung remodeling

Visit the Hardie Lab.

MD: Vanderbilt University, Nashville, TN, 1990.

Residency: Children's Hospital Medical Center, Cincinnati, OH.

Fellowship: Children's Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, 1993; Pulmonary Medicine, 1999.

Le Cras TD, Korfhagen TR, Davidson C, Schmidt S, Fenchel M, Ikegami M, Whitsett JA, Hardie WD. Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Pathol. 2010 Feb;176(2):679-86

Deshmukh HS, McLachlan A, Atkinson JJ, Hardie WD, Korfhagen TR, Dietsch M, Liu Y, Di PY, Wesselkamper SC, Borchers MT, Leikauf GD. Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production. Am J Respir Crit Care Med. 2009 Nov 1;180(9):834-45.

Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol. 2009 Jul;175(1):3-16.

Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, Hardie WD. Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2009 Nov;41(5):562-72.

Kramer EL, Mushaben EM, Pastura PA, Acciani TH, Deutsch GH, Khurana Hershey GK, Korfhagen TR, Hardie WD, Whitsett JA, Le Cras TD. Early growth response-1 suppresses epidermal growth factor receptor-mediated airway hyperresponsiveness and lung remodeling in mice. Am J Respir Cell Mol Biol. 2009 Oct;41(4):415-25.

Hardie WD. 50 Years Ago in The Journal of Pediatrics Pediatric Empyema: A Second Look at its Incidence and Importance. Kiesewetter, WB, Rusnock JR, Girdany BR. J Pediatr 1959;54:81-6. J Pediatr. 2009 Jan 1;154(1):131.

Loeb JS, Blower WC, Feldstein JF, Koch BA, Munlin AL, Hardie WD. Acceptability and repeatability of spirometry in children using updated ATS/ERS criteria. Pediatr Pulmonol. 2008 Oct;43(10):1020-4.

Hardie WD, Davidson C, Ikegami M, Leikauf GD, Le Cras TD, Prestridge A, Whitsett JA, Korfhagen TR. EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1217-25.

Deshmukh HS, Shaver C, Case LM, Dietsch M, Wesselkamper SC, Hardie WD, Korfhagen TR, Corradi M, Nadel JA, Borchers MT, Leikauf GD. Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production. Am J Respir Cell Mol Biol. 2008 Apr;38(4):446-54.

McPhail GL, Hardie WD. Cavitary lung lesions in a 2-year-old child. Respiration. 2008;76(1):117-8.

Carolyn M. Kercsmar, MD Co-Director, Division of Pulmonary Medicine

513-636-6771 carolyn.kercsmar@cchmc.org

High Res

Carolyn M. Kercsmar, MD

Co-Director, Division of Pulmonary Medicine

Director, Asthma Center

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-6771

Email carolyn.kercsmar@cchmc.org

Show All

BS: Biology, Baldwin-Wallace College, Cleveland, OH, 1972.

MD: Case Western Reserve University, Cleveland, OH, 1978.

MS: Anatomy, Case Western Reserve University, Cleveland, OH, 1978.

Kercsmar C. Exhaled nitric oxide in the diagnosis and management of childhood asthma. Ther Adv Respir Dis. 2010 Apr;4(2):71-82.

Kattan M, Kumar R, Bloomberg GR, Mitchell HE, Calatroni A, Gergen PJ, Kercsmar CM, Visness CM, Matsui EJ, Steinbach SF, Szefler SJ, Sorkness CA, Morgan WJ, Teach SJ, Gan VJ. Asthma control, adiposity, and adipokines among inner-city adolescents. J Allergy Clin Immunol. 2010 125:584-92.

Rohan J, Drotar D, McNally K, Schluchter M, Riekert K, Vavrek P, Schmidt A, Redline S, Kercsmar C. Adherence to pediatric asthma treatment in economically disadvantaged African-American children and adolescents: an application of growth curve analysis. J Pediatr Psychol. 2010 May;35(4):394-404.

Ross KR, Hart MA, Storfer-Isser A, Kibler AM, Johnson NL, Rosen CL, Kercsmar CM, Redline S. Obesity and obesity related co-morbidities in a referral population of children with asthma. Pediatr Pulmonol. 2009 Sep;44(9):877-84.

McNally KA, Rohan J, Schluchter M, Riekert KA, Vavrek P, Schmidt A, Redline S, Kercsmar C, Drotar D. Adherence to combined montelukast and fluticasone treatment in economically disadvantaged African American youth with asthma. J Asthma. 2009 Nov;46(9):921-7.

Kercsmar CM, McDowell KM. Love it or Lev it: Levalbuterol for severe acute asthma; for now, leave it. J Pediatr. 2009 155:163-64.

Short EJ, Kirchner HL, Asaad GR, Fulton S, Lewis B, Eisengart S, Baley J, Kercsmar C, Min MO, Singer LT. Long-term Sequelae of Postnatal Surfactant and Corticosteroid Therapies. BPD J Perinatol. 2008 Jul; 28(7):498-504.

Szefler SL, Mirchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, Kattan M, Pongracic JA, Teach SJ, , Bloomberg GR, Eggleston PA, Gruchalla RS, Kercsmar CM, Liu, AH, Wildfire JJ, Busse WW. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet. 2008 372:1065-72.

Kercsmar CM. Meeting the challenges of asthma: conference summary. Respir Care. 2008 Jun;53(6):787-95.

Sobande PO, Kercsmar CM. Inhaled corticosteroids in asthma management. Respir Care. 2008 May;53(5):625-33; discussion 633-4. Review.

Satish K. Madala, PhD

is assistant professor in the Division of Pulmonary Medicine at Cincinnati Children’s within the UC Department of Pediatrics. His basic research is focused on studying molecular mechanisms in pulmonary fibrosis. His current funded research programs specifically focuses on multiple stromal cell subsets and cytokines that contribute to the initiation and progression of fibrosis in the lung.
Visit the Madala Lab.

513-636-9852 satish.madala@cchmc.org

High Res

Satish K. Madala, PhD

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-9852

Email satish.madala@cchmc.org

Show All

Visit the Madala Lab.

Biography

Dr. Madala’s research interests are to identify the cellular and molecular mechanisms involved the initiation, maintenance, and progression of pulmonary fibrosis. His lab’s research tools include using molecular, biochemical and immunology methods to identify novel therapeutic targets in chronic lung diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc), and cystic fibrosis (CF). The lab’s early studies using several mouse models of fibrosis have revealed that multiple growth factors contribute to the deposition of collagen and other extracellular matrix (ECM) proteins in the lung. The lab’s recent studies have helped to define unique functions of fibrocytes and their heterogeneous interactions with other lung stromal cells in causing the expansion of adventitial and pleural fibrotic lesions in the lung.

Postdoctoral training: Wynn Lab, Immunopathogenesis Section, LPD, NIAD, NIH, Bethesda, MD.

PhD: National Institute of Nutrition, Osmania University, Hyderabad, India.

Madala SK*, Edukulla R, Davis KR, Schmidt SM, Davidson CR, Ikegami M. Hardie WD. Bone marrow-derived stromal cells are invasive and hyperproliferative and alter TGFα-induced fibrosis. Am J Respir Cell Mol Bio. 2014 Apr;50(4):777-86. * Corresponding author

Madala SK*, Edukulla R, Davis KR, Schmidt SM, Davidson CR, Kitzmiller JA, Hardie WD, Korfhagen TA. Resistin-like molecule alpha1 (Fizz1) recruits lung dendritic cells without causing pulmonary fibrosis . Respir Res . 2012 Jun 22;13:51. *Corresponding author

Madala SK, Schmidt SM, Davidson CR, Ikegami M, Susan W, Hardie WD. MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation . Am J Respir Cell Mol Bio . 2012 Mar 46(3):380-8.

Wynn TA, Barron L, Thompson RW, Madala SK, Wilson MS, Cheever AW, Ramalingam TR. Quantitative Assessment of Macrophage Functions in Repair and Fibrosis . Curr Protoc Immunol . 2011 Apr; Chapter 14:Unit14.22.

Madala SK, Dolan M, Sharma D, Ramalingam TR, Wilson MS, Mentink-Kane MM,Wynn TA. Mapping mouse IL-13 binding regions using structure modeling, molecular docking and high-density peptide microarray analysis . Proteins . 2011 Jan;79(1):282-93.

Wilson MS, Ramalingam TR, Rivollier A, Shenderov K, Mentink-Kane MM, Madala SK, Cheever AW, Artis D, Kelsall BL, Wynn TA. Colitis and intestinal inflammation in IL10-/- mice results from IL-13Rα2-mediated attenuation of IL-13 activity . Gastroenterology . 2011 Jan;140(1):254-64 .

Wilson MS, Madala SK, Ramalingam TR, Thompson RW Mentink-Kane MM, Cheever AW, Wynn TA. Bleomycin and IL-1β mediated pulmonary fibrosis is regulated by IL-10 and dependent on IL-17A . J Exp Med . 2010 Mar 15;207(3):535-52.

Madala SK, Pesce J, Ramalingam TR, Wilson MS, Thompson RW, Minnicozzi S, Mentink-Kane MM, Cheever AW,Wynn TA. Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis . J Immunol . 2010 Apr 1;184(7):3955-63.

Ramalingam TR, Pesce JT, Mentink-Kane MM, Madala SK, Cheever AW, Comeau MR, Ziegler SF, Wynn TA. Regulation of helminth-induced Th2 responses by thymic stromal lymphopoietin . J Immunol . 2009 May 15;182(10):6452-9.

Grants

Role of IL-31 in immunopathology of Systemic sclerosis (SSc). Principal Investigator. Bristol-Myers Squibb preclinical contract. 2013-2016. R03 NIAMS.

Molecular Mechanisms of Pulmonary Fibrosis. Principal Investigator. Parker B. Francis Fellowship. 2013-Dec 2016.

Karen M. McDowell, MD Director, Infant Pulmonary Function Lab

513-636-6771 karen.mcdowell@cchmc.org

High Res

Karen M. McDowell, MD

Director, Infant Pulmonary Function Lab

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-6771

Fax 513-636-4615

Email karen.mcdowell@cchmc.org

Show All

Clinical

Asthma; flexible bronchoscopy; general pediatric pulmonology; quality improvement methodologies; infant pulmonary function test

Research

Clinical asthma research; quality improvement methodologies; infant pulmonary function test

BS: College of William and Mary, Williamsburg, VA, 1983.

MS: University of Connecticut, Storrs, CT, 1986.

MD: Temple University School of Medicine, Philadelphia, PA, 1990.

Residency: Rainbow Babies and Children's Hospital, Cleveland, OH.

Fellowship: Rainbow Babies and Children's Hospital, Cleveland, OH.

Certification: Pediatric Pulmonology, 1996.

McDowell KM, Craven DI. Pulmonary complications of Down syndrome during childhood. J Pediatr. 2011 Feb;158(2):319-25.

Kercsmar CM, McDowell KM. Love It or Lev It: The Role of Levalbuterol in Acute Severe Asthma—For now, Leave it. J Pediatr. 2009 155(2):162-164.

Richards MM, Banez, GA, McDowell KM. Pediatric Puzzler. Pediatric Perspectives. April 2006.

Ogunmola N, Wyllie R, McDowell K, Kay M, Mahajan L. Endoscopic closure of esophagobronchial fistula with fibrin glue. J Pediatr Gastroenterol Nutr. 2004 38(5): 539-541.

Gary Lewis McPhail, MD Cystic Fibrosis Center Director, Division of Pulmonary Medicine

513-636-6771 gary.mcphail@cchmc.org

High Res

Gary Lewis McPhail, MD

Cystic Fibrosis Center Director, Division of Pulmonary Medicine

Associate Director, Fellowship Training Program

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-6771

Fax 513-636-4615

Email gary.mcphail@cchmc.org

Show All

Clinical

Medical education; outcomes research; quality improvement; sleep medicine; thoracic insufficiency syndrome

Research

Medical education; pulmonary vascular disease; thoracic insufficiency syndrome

MD: University of Texas Southwestern Medical Center, Dallas TX, 2001.

Residency: Children's Medical Center, University of Texas Southwestern, Dallas, TX, 2004.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2007.

Certification: Pediatrics, 2004; Pediatric Pulmonary, 2008.

McPhail GL, Weiland J, Acton JD, Ednick M, Chima A, VanDyke R, Fenchel MC, Amin RS, Seid M. Improving evidence-based care in cystic fibrosis through quality improvement. Arch Pediatr Adolesc Med. 2010 Oct;164(10):957-60.

McPhail GL, Ednick MD, Fenchel MC, VanDyke R, Chima A, Amin RS, Seid M. Improving follow-up in hospitalised children. Qual Saf Health Care. 2010 Oct;19(5):e35

Ednick M, Cohen AP, McPhail GL, Beebe D, Simakajornboon N, Amin RS. A review of the effects of sleep during the first year of life on cognitive, psychomotor, and temperament development. Sleep. 2009 Nov 1;32(11):1449-58. Review.

McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr. 2008 Dec;153(6):752-7.

McPhail GL. Coagulation disorder as a presentation of cystic fibrosis. J Emerg Med. 2010 Apr;38(3):320-2.

Amin R, Somers VK, McConnell K, Willging P, Myer C, Sherman M, McPhail G, Morgenthal A, Fenchel M, Bean J, Kimball T, Daniels S. Activity-adjusted 24-hour ambulatory blood pressure and cardiac remodeling in children with sleep disordered breathing. Hypertension. 2008 Jan;51(1):84-91.

McPhail GL, Hardie WD. Cavitary lung lesions in a 2-year-old child. Respiration. 2008;76(1):117-8.

Anjaparavanda P. Naren, PhD Thomas Boat Chair in Cystic Fibrosis Research

is a physiologist whose lab studies the cellular and molecular mechanisms of how protein-protein interactions regulate the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel in diseases such as cystic fibrosis and secretory diarrhea.

513-803-4731 anaren@cchmc.org

High Res

Anjaparavanda P. Naren, PhD

Thomas Boat Chair in Cystic Fibrosis Research

Co-Director, Cystic Fibrosis Research Center

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-803-4731

Email anaren@cchmc.org

Show All

Cystic fibrosis; secretory diarrhea.

Biography

Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-regulated chloride channel located primarily on the apical surface of epithelial cells that line various organs, including the airways and the gut. CFTR dysfunction is detrimental and may result in life-threatening medical disorders. Dr. Naren's laboratory studies two such disorders; (1) Cystic fibrosis, a lethal genetic disease that affects mostly the Caucasian population (>30,000 in USA), in which the CFTR chloride channel is HYPO-functional and (2) Secretory diarrhea, a disease affecting millions of children worldwide, in which HYPER-function of the CFTR chloride channel can occur due to infectious toxins, such as cholera toxin and E. coli enterotoxin. His lab is interested in identifying interactions between CFTR and its binding partners and defining how spatiotemporal regulation of CFTR-containing macromolecular complexes in the apical compartment of polarized epithelial cells lining the secretory epithelia regulates overall fluid secretion. Our studies will identify new drug targets for cystic fibrosis, secretory diarrhea, and other diseases resulting from CFTR dysfunction and provide insights into the etiology of diseases associated with CFTR-interacting molecules.

PhD: Biochemistry, Indian Institute of Science, Bangalore, India, 1993.

Ren A, Zhang W, Sunitha Y, Arora K, Sinha C, Moon CS, Naren AP. MAST205 Competes with CAL for Binding to CFTR to Regulate CFTR-mediated Fluid Transport. J Biol Chem. 2013 April:26;288(17):12325-34.

Yarlagadda S, Zhang W, Penmatsa H, Ren A, Arora K, Naren AP*, Khan FA, Donnellan C, Srinivasan S, Stokes D, Kappes JC. A Young Hispanic with c.1646G>A Mutation Exhibits Severe Cystic Fibrosis Lung Disease: Is Ivacaftor an Option for Therapy? Am J Respir Crit Care Med. 2012 Oct:1 186(7):694-6. (*Corresponding Author)

Zhang W, Penmatsa H, Ren A, Punchihewa C, Lemoff A, Yan B, Fujii N, Naren AP. Functional regulation of CFTR-containing macromolecular complexes: a small-molecule inhibitor approach. Biochem J. 2011 April:15;435(2):451–62

Penmatsa H, Zhang W, Yarlagadda S, Li C, Conoley VG, Yue J, Bahouth SW, Buddington RK, Zhang G, Nelson DJ, Sonecha MD, Manganiella V, Wine JJ, Naren AP. Compartmentalized cyclic adenosine 3’,5’-monophosphate at the plasma membrane clusters PDE3A and cystic Fibrosis transmembrane conductance regulator into microdomains. Mol Biol Cell. 2010 Mar:15;21:1097-110.

Li C, Krishnamurthy PC, Penmatsa H, Marrs KL, Wang XQ, Zaccolo M, Jalink K, Li M, Nelson DJ, Schuetz JD, Naren AP. Spatiotemporal Coupling of cAMP Transporter to CFTR Chloride Channel Function in the Gut Epithelia. Cell. 2007 Nov:30;131(5): 940-51.

Li C, Dandridge KS, Di A, Marrs KL, Harris EL, Roy K, Jackson JS, Makarova NV, Fujiwara Y, Farrar, PL, Nelson DJ, Tigyi GJ, Naren AP. Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. J Exp Med. 2005 Oct:3; 202(7):975-86.

Naren AP, Cobb B, Li C, Roy K, Nelson D, Heda GD, Liao J, Kirk KL, Sorscher EJ, Hanrahan J, Clancy JP. A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc Natl Acad Sci USA. 2003 Jan:7;100(1):342-46.

Naren AP, Anke D, Cormet-Boyaka E, Boyaka PN, McGhee JR, Zhou W, Akagawa K, Fujiwara T, Thome U, Engelhardt JF, Nelson DJ, Kirk KL. Syntaxin 1A is expressed in airway epithelial cells, where it modulates CFTR Cl(-) currents. J Clin Invest. 2000 Feb;105(3):377-86.

Naren AP, Cormet-Boyaka E, Fu J, Villain M, Blalock E, Quick MW, Kirk KL. CFTR Chloride channel regulation by an interdomain interaction. Science. 1999 Oct:15;286(5439):544-8.

Naren AP, Nelson DJ, Xie W, Jovov B, Tousson A, Pevsner J, Bennett MK, Benos DJ, Quick MW, Kirk KL. Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms. Nature. 1997 Nov:20;390(6657):302-5.

Grants

Inhibition of a cAMP transporter (MRP4) in the gut induces diarrhea. Principal Investigator. National Institutes of Health. June 2009-Apr 2018. DK080834.

LPA2-receptor containing complexes in regulating secretory diarrhea. Principal Investigator. July 2011-June 2020. RO1 (DK093045).

CF-Patient Specific Enteroids from Small Intestine and Colon. Principal Investigator. Cystic Fibrosis Foundation. July 2014-June 2016. NAREN14XXO.

Characterization of an inhibitory protein complex for cystic fibrosis therapy. Collaborator. Aug 2014-July 2019. RO1 (HL123535).

Personalizing Cystic Fibrosis Research Translation. Principal Investigator/Director-CF Human Model Systems Core. CFF-Research Development Project. July 2015-June 2019. CLANCY15R0.

Demonstrate that GC-C modulation of CFTR in the gut epithelia using enteroids from CF patients increases intestinal fluid secretion. Principal Investigator. Ironwood Grant. June 2015-May 2016. LIN-PH-44.

Marc G. Schecter, MD Medical Director, Pediatric Lung Transplant Program

is a pediatric pulmonologist with a special interest in pediatric lung transplantation. His research has focused on the pulmonary microbiome and lung transplant, health related quality of life following lung transplant, and other clinical studies investigating lung transplantation in children.

513-636-6771 marc.schecter@cchmc.org

High Res

Marc G. Schecter, MD

Medical Director, Pediatric Lung Transplant Program

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-6771

Email marc.schecter@cchmc.org

Show All

Specialties

Lung transplantation

MD: University of Texas Medical Branch, Galveston, TX, 2000.

Residency: University of Texas Health Science Center, Houston, TX, 2003.

Fellowship: University of Texas Health Science Center, Houston, TX, 2006.

Certifications: Pediatrics, 2003; Pediatric Pulmonary, 2006.

Yousef S, Benden C, Boyer D, Elidemir O, Frischer T, Goldfarb S, Lopez-Mitnik G, Mallory G, Visner G, Westall G, Schecter MG. Lung transplantation in children following bone marrow transplantation: a multi-center experience. Pediatric Transplant. 2013 May;17(3):231-6.

Khan MS, Heinle JS, Samayoa AX, Adachi I, Schecter MG, Mallory GB, Morales DL. Is lung transplantation survival better in infants? Analysis of over 80 infants. J Heart Lung Transplant. 2013 Jan;32(1):44-9.

Rama JA, Fan LL, Faro A, Elidemir O, Morales DL, Heinle JS, Smith EO, Hazen ML, Moonnumakal SP, Mallory GB, Schecter MG. Lung Transplantation for childhood diffuse lung disease. Pediatr Pulmonol. 2013 May;48(5):490-6.

Vece TJ, Schecter MG, Gatti RA, Tunuguntla R, Garcia CK, Langston C, Dishop MK, Moore RH, Fan LL. Rapid and progressive pulmonary fibrosis in 2 families with DNA repair deficiencies of undetermined etiology. J Pediatr. 2012 Apr;160(4):700-702.e3.

Schaellibaum G, Lammers AE, Faro A, Moreno-Galdo A, Parakininkas D, Schecter MG, Solomon M, Boyer D, Conrad C, Frischer T, Wong J, Boehler A, Benden C. Bilateral lung transplantation for pediatric idiopathic pulmonary arterial hypertension: a multi-center experience. Pediatr Pulmonol. 2011 Nov;46(11):1121-7.

Scully BB, Zafar F, Schecter MG, Rossano JW, Mallory GB Jr, Heinle JS, Morales DL. Lung Retransplant in Children: appropriate when selectively applied. Ann Thorac Surg. 2011 Feb;91(2):574-9.

Rosen JB, Schecter MG, Heinle JS, McKenzie ED, Morales DL, Dishop MK, Danziger-Isakov L, Mallory GB, Elidemir O. Clostridium Difficile colitis in children following lung transplantation. Pediatr Transplant. 2010 Aug;14(5):651-6.

Michael Seid, PhD Director, Health Outcomes and Quality Care Research, Pulmonary Medicine and James M. Anderson Center for Health Systems Excellence

The basic science behind what to do to improve health include genetics, biology, and chemistry, and physiology; the basic science behind how to do it right is behavioral and social science. Dr. Seid's Lab applies behavioral and social science to answer the question ‘What does it take to make sure the right treatment gets to the right child in the right way at the right time, every time?’ The lab takes a noncategorical approach to answering this question, as there are many more similarities than differences across diseases in what it takes to get things right. They also recognize that answering this question requires expertise from many areas: patients and families; clinicians; social scientists like psychologists, sociologists, economists, and anthropologists; designers; story-tellers and artists; systems engineers; organizers; technologists; health informaticians; and epidemiologists and other statisticians.

Visit the Seid Lab.

513-803-0083 michael.seid@cchmc.org

High Res

Michael Seid, PhD

Director, Health Outcomes and Quality Care Research, Pulmonary Medicine and James M. Anderson Center for Health Systems Excellence

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-803-0083

Email michael.seid@cchmc.org

Show All

Health care quality and outcomes

Visit the Seid Lab.

Biography

Michael Seid, PhD, is director of Health Outcomes and Quality of Care Research in the Division of Pulmonary Medicine and a core faculty in the James M. Anderson Center for Health Systems Excellence at Cincinnati Children's Hospital Medical Center within the UC Department of Pediatrics. Dr. Seid applies behavioral and social science to the question ‘What does it take to make sure the right treatment gets to the right child in the right way at the right time, every time?’

Dr. Seid has worked at the Center for Child Health Outcomes at Children's Hospital, San Diego and was a behavioral / research scientist at the RAND Corporation. He has been principal and co-principal investigator of several large multidisciplinary research studies, collaborates with investigators at Cincinnati Children's and beyond, and publishes widely in such journals as Medical Care, HSR: Health Services Research, Archives of Pediatrics and Adolescent Medicine, Pediatrics, American Journal of Medical Quality, the Journal of Ambulatory Pediatrics, and Milbank Quarterly.

Dr. Seid has served as the chair of Children's Hospital San Diego's Institutional Review Board, as a member of the Health Care Quality and Effectiveness Research (HCQER) Study Section at the Agency for Healthcare Quality and Research, and on several national and local expert panels. He is on the Review Board of the Journal of Clinical Outcomes Management and an ad hoc reviewer for Health Services Research, Pediatrics and the Journal of Ambulatory Pediatrics.

PhD: Psychology, University of Illinois, Urbana-Champaign, 1995.

Grossoehme DH, Ragsdale JR, Snow A, Seid M. We were Chosen as a Family: Parents' Evolving Use of Religion when Their Child has Cystic Fibrosis. J Relig Health. 2011 Mar 16.

McPhail GL, Weiland J, Acton JD, Ednick M, Chima A, VanDyke R, Fenchel MC, Amin RS, Seid M. Improving evidence-based care in cystic fibrosis through quality improvement. Arch Pediatr Adolesc Med. 2010 Oct;164(10):957-60.

Muething SE, Conway PH, Kloppenborg E, Lesko A, Schoettker PJ, Seid M, Kotagal U. Identifying causes of adverse events detected by an automated trigger tool through in-depth analysis. Qual Saf Health Care. 2010 Oct;19(5):435-9.

Grossoehme DH, Ragsdale J, Cotton S, Wooldridge JL, Grimes L, Seid M. Parents' religious coping styles in the first year after their child's cystic fibrosis diagnosis. J Health Care Chaplain. 2010 Jul;16(3-4):109-22.

Grossoehme DH, Ragsdale J, Wooldridge JL, Cotton S, Seid M. We can handle this: parents' use of religion in the first year following their child's diagnosis with cystic fibrosis. J Health Care Chaplain. 2010 Jul;16(3-4):95-108.

Stevens GD, Seid M, Pickering TA, Tsai KY. National disparities in the quality of a medical home for children. Matern Child Health J. 2010 Jul;14(4):580-9.

Ernst MM, Wooldridge JL, Conway E, Dressman K, Weiland J, Tucker K, Seid M. Using Quality Improvement Science to Implement a Multidisciplinary Behavioral Intervention Targeting Pediatric Inpatient Airway Clearance. J Pediatr Psychol. 2010 Jan-Feb; 35(1):1.

Seid M, Limbers CA, Driscoll KA, Opipari-Arrigan LA, Gelhard LR, & Varni JW. Reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory™ (PedsQL™) Generic Core Scales and Asthma Symptoms Scale in vulnerable children with asthma. Journal of Asthma. 2010;47:170-177.

Wirtschafter DD, Pettit J, Kurtin P, Dalsey M, Chance K, Morrow HW, Seid M, Byczkowski TL, Huber TP, Milstein JM, Bowles SM, Fichera S, Kloman S. A statewide quality improvement collaborative to reduce neonatal central line-associated blood stream infections. J Perinatol. 2010 Mar;30(3):170-81.

Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari NA, Donauer S, Henderson D, Ambrose S, Kent D, Poehling K, Weinberg GA, Griffin MR, Hall CB, Finelli L, Bridges C, Staat MA; New Vaccine Surveillance Network (NVSN). High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine. 2010 Jul 12;28(31):4913-9.

Robert E. Wood, PhD, MD Director, Pulmonary Bronchoscopy Department

513-636-6771 robertewood@cchmc.org

High Res

Robert E. Wood, PhD, MD

Director, Pulmonary Bronchoscopy Department

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-6771

Fax 513-636-3845

Email robertewood@cchmc.org

Show All

Clinical

Bronchology

Research

Bronchology; pulmonary alveolar proteinosis

Biography

Dr. Robert Wood, PhD, MD, is a pediatric pulmonary specialist, with particular interest in bronchoscopy. He has played a major role in the development of instrumentation and techniques for flexible bronchoscopy in pediatric patients. He is recognized as a teacher of endoscopic techniques, and has published many papers and book chapters on the subject. Additionally, he has extensive experience with clinical problems in pediatric pulmonary medicine, especially children with complex airway problems and cystic fibrosis.

Before coming to Cincinnati Children's Hospital Medical Center, Dr. Wood was on the faculty of Case Western Reserve University in Cleveland, Ohio (1976 to 1983), and the University of North Carolina at Chapel Hill (1983 to 1999).

PhD: Medical Physiology, Vanderbilt University, Nashville, TN, 1968.

MD: Vanderbilt University, Nashville, TN, 1970.

Residency: Pediatrics, Duke University Medical Center, Durham, NC, 1970 to 1972.

Fellowship: Pediatric Metabolism, National Institute of Arthritis, Metabolism, and Digestive Diseases, Bethesda, MD, 1972 to 1974; Pediatric Pulmonology, Case Western Reserve University, Cleveland, OH; Rainbow Babies and Children's Hospital, Cleveland, OH, 1974 to 1976.

Certification: Pediatrics, 1976; Pediatric Pulmonology, 1986, 1997.

Visit the Center for Pulmonary Imaging Research Lab.

Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, Wert SE, Rubin BK, Kevill K, Chalk C, Whitsett JA, Stevens C, Nogee LM, Campo I, Trapnell BC. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010 Nov 15;182(10):1292-304.

Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61.

Abman S, Jobe A, Chernick V, Blaisdell C, Castro M, Ramirez MI, Gern JE, Cutting G, Redding G, Hagood JS, Whitsett J, Abman S, Raj JU, Barst R, Kato GJ, Gozal D, Haddad GG, Prabhakar NR, Gauda E, Martinez FD, Tepper R, Wood RE, Accurso F, Teague WG, Venegas J, Cole FS, Wright RJ, Gail D, Hamvas A, Kercsmar C, Kiley J, Weinmann G; NHLBI working group report. Strategic plan for pediatric respiratory diseases research: an NHLBI working group report. Pediatr Pulmonol. 2009 Jan;44(1):2-13.

Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Kosepglu ST, Link B, Martin RA, Molter DW, MuAoz Rojas MV, Ogilvie JW, Parini R, Ramaswami U, Scarpa M, Schwartz IV, Wood RE, Wraith E. Multidisciplinary Management of Hunter Syndrome. Pediatrics. 2009; 124:e1228-39.

Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, Smolarek T, Dishop MK, Wert SE, Whitsett JA, Grabowski G, Carey BC, Stevens C, van der Loo JC, Trapnell BC. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008 Nov 24;205(12):2703-10.

Wood RE. Evaluation of the upper airway in children. Curr Opin Pediatr. 2008 Jun;20(3):266-71. Review.

Boesch RP, Daines C, Willging JP, Kaul A, Cohen AP, Wood RE, Amin RS. Advances in the diagnosis and management of chronic pulmonary aspiration in children. Eur Respir J. 2006 Oct;28(4):847-61. Review.

Zur KB, Wood RE, Elluru RG. Pediatric postcricoid vascular malformation: a diagnostic and treatment challenge. Int J Pediatr Otorhinolaryngol. 2005 Dec;69(12):1697-701.

Lim LH, Cotton RT, Azizkhan RG, Wood RE, Cohen AP, Rutter MJ. Complications of metallic stents in the pediatric airway. Otolaryngol Head Neck Surg. 2004 Oct;131(4):355-61.

Wood RE. The emerging role of flexible bronchoscopy in pediatrics. Clin Chest Med. 2001 Jun;22(2):311-7, viii. Review.

Jason C. Woods, PhD Director, Center for Pulmonary Imaging Research

is an imaging scientist who focuses on basic and translational pulmonary MRI and CT. His lab studies new methods for in-vivo assessment of regional pulmonary function, microstructure and physiology using hyperpolarized gases (3He and 129Xe) and 1H MRI, in addition to multi-volume CT. As new therapeutics for pulmonary diseases are developed, these new methods will be used for efficacy assessment and potential image guidance.

513-803-4463 jason.woods@cchmc.org

High Res

Jason C. Woods, PhD

Director, Center for Pulmonary Imaging Research

Academic Affiliations

Professor, UC Department of Pediatrics

UC Department of Radiology

Phone 513-803-4463

Email jason.woods@cchmc.org

Show All

Visit the Center for Pulmonary Imaging Research Lab.

Hyperpolarized gas; pulmonary MRI; translational studies; image-guided pulmonary interventions

Biography

Dr. Woods is one of the world’s experts on hyperpolarized-gas MRI and the use of such gas MRI to measure regional lung function, microstructure and physiology. He began his career in physics, radiology, and the dean's office at Washington University in St Louis, and moved to Cincinnati Children's in 2013 to apply new imaging techniques to pediatric translational research. He leads multiple team projects related to the multidisciplinary study of lung structure, function, biology and physiology. In particular, imaging applications to the study of cystic fibrosis, BPD, rare-lung diseases, and allograft rejection are all active areas of current research.

Dr. Woods directs the Center for Pulmonary Imaging Research at Cincinnati Children’s Hospital Medical Center. The center is a multidisciplinary research and training program at the intersection of pulmonary medicine, radiology, and neonatology.

PhD: Washington University, St. Louis, MO, 2002.

Postdoctoral: Washington University, St. Louis, MO, 2004.

Roach DJ, Crémillieux Y, Fleck RJ, Brody AS, Serai SD, Szczesniak RD, Kerlakian S, Clancy JP, Woods JC. Ultrashort Echo-Time Magnetic Resonance Imaging Is a Sensitive Method for the Evaluation of Early Cystic Fibrosis Lung Disease. Annals ATS. 2016.

Thomen RP, Walkup LL, Roach DJ, Cleveland ZI, Clancy JP, Woods JC. Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatrics. J Cyst Fibr. 2016.

Stein JM, Walkup LL, Brody AS, Fleck RJ, Woods JC. Quantitative CT characterization of pediatric lung development using routine clinical imaging. Pediatric Radiology. 2016.

Roach DJ, Crémillieux Y, Serai SD, Thomen RP, Wang H, Zou Y, Benzaquen S, Szczesniak RD, Woods JC. Morphological and quantitative evaluation of emphysema in COPD patients: a comparative study of MRI with HRCT. J Magn Reson Imag. 2016.

Walkup LL, Thomen RP, Akinyi TG, Watters E, Ruppert K, Clancy JP, Woods JC, Cleveland ZI. Feasibility, tolerability, and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and subjects with cystic fibrosis. Pediatric Radiology. 2016.

Higano NS, Hahn AD, Tkach JA, Cao X, Walkup LL, Thomen RP, Merhar SL, Kingma PS, Fain SB, Woods JC. Retrospective respiratory self-gating and removal of bulk motion in pulmonary UTE MRI of neonates and adults. Magn Reson Med. 2016.

Hahn AD, Higano NS, Walkup LL, Thomen RP, Cao X, Merhar SL, Tkach JA, Woods JC, Fain SB. Pulmonary MRI of neonates in the intensive care unit using 3-D ultrashort echo time and a small footprint MRI system. J Magn Reson Imag. 2016.

Thomen RP, Quirk JD, Roach D, Egan-Rojas T, Ruppert K, Yusen RD, Altes TA, Yablonskiy DA, Woods JC. Direct comparison of 129Xe diffusion measurements with quantitative histology in human lungs. Magn Reson Med. 2016.

Saito A, Nikolaidis NM, Amlal H, Uehara Y, Gardner JC, LaSance K, Pitstick LB, Bridges JP, Wikenheiser-Brokamp KA, McGraw DW, Woods JC, Sabbagh Y, Schiavi SC, Altinişik G, Jakopović M, Inoue Y, McCormack FX. Modeling pulmonary alveolar microlithiasis by lung epithelial deletion of the NPT to be sodium phosphate coat transporter feels novel biomarkers and strategies for treatment. Sci Transl Med. 2015 Nov 11;7(313):313ra181.

Grants

UTE MRI to monitor CF lung disease and responses to CF TR modulation young children. Principal Investigator. National Heart, Lung, and Blood Institute. June 2016–May 2021.

Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis. Investigator. National Heart, Lung, and Blood Institute. Sep 2016–Aug 2021.

Regional Biomarkers of Peripheral Lung Disease in Cystic Fibrosis. Investigator. Cystic Fibrosis Foundation. Apr 2016–Mar 2019.

Severe Asthma Research Program (SARP). Investigator. NHLBI. Aug 2011–Jul 2017.

Assem G. Ziady, PhD Director, The Cystic Fibrosis Biomarker Analysis and Assay Development RDP Core

uses biochemistry, proteomics, and molecular biology to study the interaction between the antioxidant response element (ARE) and inflammatory signaling in epithelial cells, with a major focus on Nrf2 dysfunction in cystic fibrosis and COPD. He also designs nonviral DNA vectors for lung delivery and examine their delivery mechanistically. The overall goal of his lab is to understand the systems biology of inflammation in chronic lung disease.
Visit the Ziady Lab.

513-803-9094 assem.ziady@cchmc.org

High Res

Assem G. Ziady, PhD

Director, The Cystic Fibrosis Biomarker Analysis and Assay Development RDP Core

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Associate Professor, Case Western Reserve University

Phone 513-803-9094

Email assem.ziady@cchmc.org

Show All

Cystic fibrosis; redox mediated inflammatory signaling; nonviral gene transfer to the lung; biomarkers of disease severity and response to therapy.
Visit the Ziady Lab.

Biography

Dr. Ziady received his undergraduate education at Boston College in biochemistry in 1993. He completed his graduate studies on cell physiology and received his PhD degree in 1999 from Case Western Reserve University. Following his postdoctoral training at the Department of Pediatrics at Case Western Reserve University, he began a year-long externship at the Cleveland Clinic Proteomic facility in early 2002. In 2003, Dr. Ziady joined the faculty at the Case Western Reserve University Department of Pediatrics as assistant professor. In 2011, Dr. Ziady joined the faculty at the Emory University Department of Pediatrics as an associate professor and served as the associate director of Cystic Fibrosis Basic & Translational Research at Emory University.

In 2014, Dr. Ziady was recruited by the CF program at Cincinnati Children’s Hospital Medical Center, where he joined the faculty as associate professor of pediatrics within the UC College of Medicine in November. Dr. Ziady’s research has been supported by the State of Ohio, the Cystic Fibrosis Foundation, and the National Institutes of Health. His laboratory focuses on the differential regulation of Nrf2 signaling pathways in the inflammatory lung disease observed cystic fibrosis. Dr. Ziady's lab also has unique expertise in developing and characterizing DNA nanoparticles for nonviral gene delivery to the lung, liver, and brain. Finally, Dr. Ziady’s lab has expertise in proteomic analyses for biomarker discovery and the examination of systems biology of various tissues. He is an inventor on five patents (2 USA, 2 EU, and 1 international) pertaining to DNA nanoparticles, and one provisional patent pertaining to modulation of inflammatory signaling. In the past 15 years, he has authored 33 manuscripts and book chapters, has an h-index of 19, and has been invited to present 42 talks on his work at national and international conferences and institutions.

BS: Biochemistry, Boston College, Boston, MA, 1993.

PhD: Cell Physiology, Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, 1999.

Postdoctoral Fellowship: Non-viral gene transfer, Pediatrics, Case Western Reserve University, Cleveland, OH, 2002.

Externship: Proteomic analysis of redox mediated inflammation in CF, Cell Biology, Cleveland Clinic Foundation, Cleveland, OH, 2003.

Ziady AG, Hansen J. Redox balance in Cystic Fibrosis. Int J Biochem Cell Biol. 2014 Jul;52:113-23.

Cheng Y, Doane TL, Chuang CH, Ziady A, Burda C. Near infrared light-triggered drug generation and release from gold nanoparticle carriers for photodynamic therapy. Small. 2014;10(9):1799-1804. (Joint corresponding author with C. Burda).

Ziady AG, Sokolow A, Shank S, Corey D, Myers R, Plafker S, Kelley TJ. Interaction with CREB binding protein modulates the activities of Nrf2 and NF-κB in Cystic Fibrosis Airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2012;302(11):L1221-1231.

Yurek DM, Fletcher AM, McShane M, Kowalczyk TH, Padegimas L, Weatherspoon MR, Kaytor MD, Cooper MJ, Ziady AG. DNA Nanoparticles: Detection of long-term transgene activity in brain using bioluminescence imaging. Mol Imaging. 2011;10(5):327-339.

Lancioni CL, Li Q, Thomas JJ, Ding X, Thiel B, Drage MG, Pecora ND, Ziady AG, Shank S, Harding CV, Boom WH, Rojas RE. Mycobacterium tuberculosis lipoproteins induce human memory CD4+ T cell activation via toll-like receptors 1 and 2. Infect and Immun. 2011;79(2):663-673.

Chen X, Shank S, Davis PB, Ziady AG. Nucleolin-mediated cellular trafficking of DNA nanoparticle is lipid raft and microtubule dependent and can be modulated by glucocorticoid. Molec Ther. 2011;19(1):93-102.

Ziady AG, Kotlarchyk M, Bryant L, McShane M, Lee Z. Bioluminescent imaging of reporter gene expression in the lungs of wildtype and model mice following the administration of PEG-stabilized DNA nanoparticles. Microsc Res Tech. 2010;73(9):918-928.

Nichols DP, Ziady AG, Shank SL, Eastman JF, Davis PB. The Triterpenoid CDDO limits inflammation in preclinical models of Cystic Fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol. 2009;297(5):L828-836.

Yurek DM, Fletcher AM, Smith GM, Seroogy KB, Ziady AG, Molter J, Kowalczyk TH, Padegimas L, Cooper MJ. Long-term transgene expression in the Central Nervous System using DNA nanoparticles. Mol Ther. 2009;17(4):641-650.

Chen J, Kinter M, Shank S, Cotton C, Kelley TJ, Ziady AG. Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production. PLoS ONE. 2008;3(10):e3367.

Grants